LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

Search

Coherus Biosciences Inc

Chiusa

SettoreSettore sanitario

0.75 -1.32

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

0.74

Massimo

0.77

Metriche Chiave

By Trading Economics

Entrata

-40M

-51M

Vendite

-17M

54M

P/E

Media del settore

4.08

56.602

EPS

-0.35

Margine di Profitto

-93.632

Dipendenti

228

EBITDA

-40M

-44M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+560.53% upside

Dividendi

By Dow Jones

Utili prossimi

7 ago 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

1.8M

118M

Apertura precedente

2.07

Chiusura precedente

0.75

Notizie sul Sentiment di mercato

By Acuity

73%

27%

349 / 382 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Weak Bearish Evidence

Coherus Biosciences Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

18 mag 2025, 23:47 UTC

Discorsi di Mercato

Nikkei May Trade Rangebound Amid Uncertainty Over U.S. Tariffs -- Market Talk

18 mag 2025, 23:40 UTC

Discorsi di Mercato

Gold Rises Amid Concerns Over U.S. Fiscal Deficit -- Market Talk

18 mag 2025, 18:00 UTC

Utili

Tax Bill News; Target, Home Depot, and Snowflake Earnings; and More Stock Market News to Watch This Week -- Barrons.com

18 mag 2025, 17:01 UTC

Notizie principali

GM Is Fighting California on EVs. This Is What It Wants to Overturn and Why. -- Barrons.com

18 mag 2025, 16:20 UTC

Utili

Tesla Demand Hasn't Rebounded Yet. Watch China This Week. -- Barrons.com

18 mag 2025, 12:09 UTC

Notizie principali

Trump Sounds Upbeat on Ukraine Cease-Fire as Russia Unleashes Drone Barrage -- WSJ

17 mag 2025, 17:15 UTC

Notizie principali

Trump Attacks Walmart for Tariff-Related Price Increases -- WSJ

17 mag 2025, 09:30 UTC

Notizie principali
Utili

In a Trade War, Walmart Lacks Some of Amazon's Ammunition -- Heard on the Street -- WSJ

17 mag 2025, 08:20 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

17 mag 2025, 08:20 UTC

Discorsi di Mercato
Utili

Financial Services Roundup: Market Talk

16 mag 2025, 23:18 UTC

Notizie principali

U.S. Loses Last Triple-A Credit Rating -- 2nd Update

16 mag 2025, 22:30 UTC

Notizie principali

U.S. Loses Last Triple-A Credit Rating -- Update

16 mag 2025, 21:56 UTC

Discorsi di Mercato

Fitch Raises Greece's Outlook to Positive From Stable -- Market Talk

16 mag 2025, 21:56 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

16 mag 2025, 21:54 UTC

Notizie principali

U.S. Loses Last Triple-A Credit Rating -- WSJ

16 mag 2025, 21:22 UTC

Discorsi di Mercato

Moody's Says U.S. Fiscal Performance Likely to Deteriorate -- Market Talk

16 mag 2025, 21:17 UTC

Discorsi di Mercato

Treasury Yields Rise, Dollar Falls After Moody's Cuts U.S. Credit Rating -- Market Talk

16 mag 2025, 21:17 UTC

Notizie principali

The Score: UnitedHealth, Walmart, Coinbase Global and More Stocks That Moved on the Week's News -- WSJ

16 mag 2025, 21:05 UTC

Discorsi di Mercato

Moody's Downgrades U.S. Credit Rating Due to Deficit, Debts -- Market Talk

16 mag 2025, 20:55 UTC

Acquisizioni, Fusioni, Takeovers

What's Next for Cable Giant Comcast After Charter-Cox Merger -- Barrons.com

16 mag 2025, 20:50 UTC

Discorsi di Mercato
Utili

Financial Services Roundup: Market Talk

16 mag 2025, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

16 mag 2025, 20:37 UTC

Notizie principali

Trade Progress Sparks Bullish Week for Wall Street -- WSJ

16 mag 2025, 20:33 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Dick's-Foot Locker Deal Looks Like a Bet on Nike's Turnaround -- Market Talk

16 mag 2025, 20:30 UTC

Acquisizioni, Fusioni, Takeovers

Galaxy Digital Begins U.S. Trading as Bitcoin Keeps Powering Ahead -- Barrons.com

16 mag 2025, 20:18 UTC

Notizie principali

Major U.S. Stock Indexes Rise; U.S. Running Out of Patience for Trade Deals -- WSJ

16 mag 2025, 20:16 UTC

Notizie principali

Justice Department Wants to Spare Boeing From Guilty Plea Over 737 MAX Charges -- 3rd Update

16 mag 2025, 20:15 UTC

Utili

Tesla Stock Rises. Even Hedge Fund Sales Can't Keep It Down. -- Barrons.com

16 mag 2025, 20:11 UTC

Acquisizioni, Fusioni, Takeovers

Henry Schein: William K. Daniel Joins Board

16 mag 2025, 20:10 UTC

Acquisizioni, Fusioni, Takeovers

Henry Schein: Strategic Investment by KKR Completed

Confronto tra pari

Modifica del prezzo

Coherus Biosciences Inc Previsione

Obiettivo di Prezzo

By TipRanks

560.53% in crescita

Previsioni per 12 mesi

Media 5.02 USD  560.53%

Alto 7 USD

Basso 1.05 USD

Basato su 5 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Coherus Biosciences Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

5 ratings

4

Acquista

1

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

0.9209 / 1.05Supporto e resistenza

A breve termine

Weak Bearish Evidence

A termine intermedio

Weak Bullish Evidence

A lungo termine

Weak Bearish Evidence

Sentiment

By Acuity

349 / 382 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove ribassiste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Coherus Biosciences Inc

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27. It is also developing CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody selectively targeting CCR8, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, an antibody targeting human ILT4 designed to improve anti-PD-1 clinical benefit by transforming an unfavorable TME to a more favorable TME. In addition, the company's licensed immuno-oncology programs include NZV930, an antibody designed to inhibit cluster of differentiation 73; and GSK4381562, an antibody targeting CD112R for the treatment of solid tumors. Further, it offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis. It collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc., as well as Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.